Stock listing

NSE:LAURUSLABS Laurus Labs Ltd. Share Price

Home listing (NSE) of Laurus Labs Ltd.

Follow Laurus Labs Ltd. into a list and get an email when it puts out news.

Share price · NSE:LAURUSLABS

₹2,294.60 INR -27.90 (-1.2%)

Close on Nov 20, 2026

Past year +132.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₹2,286.80 – ₹2,320.00 INRNov 20, 2026
Volume
878,794 sharesNov 20, 2026
Market cap
₹1.24T INRAt the close on Nov 20, 2026 · price × 540.3M shares outstanding
52-week range
₹917.95 – ₹2,488.00 INRLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₹5.37B INRMedian day 1.63M shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Laurus Labs Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NSE:LAURUSLABS · Home₹2,294.60 INR-27.90 (-1.2%)878,794₹2,294.10₹2,320.00₹2,286.80₹2,322.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NSE:LAURUSLABS · INR, adjusted for splits

DayCloseChange%OpenHighLowVolume
₹2,294.60-27.90-1.2%₹2,294.10₹2,320.00₹2,286.80878,794
₹2,322.50-15.50-0.7%₹2,345.00₹2,362.60₹2,317.001,611,891
₹2,338.00+118.00+5.3%₹2,220.00₹2,348.80₹2,214.804,887,888
₹2,220.00-204.00-8.4%₹2,430.00₹2,439.00₹2,190.006,836,877
₹2,424.00+24.00+1.0%₹2,400.00₹2,446.90₹2,394.002,277,547
₹2,400.00-29.00-1.2%₹2,427.00₹2,434.20₹2,380.001,764,909
₹2,429.00-25.00-1.0%₹2,480.00₹2,488.00₹2,416.904,133,906
₹2,454.00+114.00+4.9%₹2,351.50₹2,480.00₹2,351.504,026,300
₹2,340.00-6.00-0.3%₹2,329.70₹2,341.50₹2,309.101,445,360
₹2,346.00+22.20+1.0%₹2,328.30₹2,346.00₹2,288.201,448,875
₹2,323.80+0.800.0%₹2,291.00₹2,343.90₹2,285.603,218,928
₹2,323.00-25.00-1.1%₹2,350.10₹2,354.90₹2,252.404,025,877
₹2,348.00-57.50-2.4%₹2,406.00₹2,441.90₹2,347.003,047,198
₹2,405.50+161.50+7.2%₹2,246.60₹2,405.50₹2,206.107,909,825
₹2,244.00+62.10+2.8%₹2,190.00₹2,244.00₹2,166.002,898,447
₹2,181.90+39.90+1.9%₹2,142.00₹2,198.80₹2,131.702,200,547
₹2,142.00+83.10+4.0%₹2,075.00₹2,143.10₹2,067.403,116,290
₹2,058.90+88.90+4.5%₹1,960.00₹2,058.90₹1,951.601,858,038
₹1,970.00-32.50-1.6%₹1,987.50₹2,009.60₹1,933.501,893,589
₹2,002.50-10.00-0.5%₹1,993.50₹2,019.80₹1,956.601,538,717
₹2,012.50-56.50-2.7%₹2,052.90₹2,079.80₹1,993.401,275,844
₹2,069.00+8.90+0.4%₹2,060.10₹2,089.00₹2,052.201,133,053
₹2,060.10+41.60+2.1%₹2,030.40₹2,086.00₹2,028.701,606,547
₹2,018.50-18.40-0.9%₹2,025.00₹2,046.30₹2,008.00858,713
₹2,036.90-22.50-1.1%₹2,049.00₹2,057.30₹2,019.201,301,046
₹2,059.40-9.80-0.5%₹2,047.10₹2,065.00₹2,007.801,141,354
₹2,069.20+32.60+1.6%₹2,044.10₹2,069.20₹2,036.101,417,097
₹2,036.60+38.70+1.9%₹1,997.90₹2,048.00₹1,988.901,358,268
₹1,997.90-54.90-2.7%₹2,055.00₹2,055.00₹1,997.901,394,208
₹2,052.80+2.80+0.1%₹2,052.00₹2,065.20₹2,035.601,499,990
₹2,050.00+78.60+4.0%₹1,968.90₹2,054.90₹1,958.002,197,316
₹1,971.40-12.60-0.6%₹1,994.00₹2,002.00₹1,955.101,374,138
₹1,984.000.000.0%₹1,984.00₹1,984.00₹1,984.000
₹1,984.00+4.00+0.2%₹1,973.60₹2,006.90₹1,952.101,459,687
₹1,980.00+1.00+0.1%₹1,993.00₹2,001.60₹1,955.101,397,926
₹1,979.00-31.70-1.6%₹2,020.70₹2,024.90₹1,979.002,431,575
₹2,010.70+3.70+0.2%₹2,000.00₹2,012.30₹1,984.80950,451
₹2,007.00-19.20-0.9%₹2,026.00₹2,040.00₹1,979.201,442,142
₹2,026.20-7.80-0.4%₹2,021.10₹2,055.30₹2,020.001,388,039
₹2,034.00+27.50+1.4%₹2,009.50₹2,037.20₹1,999.701,363,988
₹2,006.50-11.00-0.5%₹2,018.00₹2,032.80₹2,002.201,487,044
₹2,017.50+63.50+3.2%₹1,966.60₹2,023.50₹1,963.802,170,267
₹1,954.00+5.90+0.3%₹1,962.00₹1,982.00₹1,954.002,655,873
₹1,948.10+42.60+2.2%₹1,898.00₹1,964.50₹1,894.801,645,108
₹1,905.50-21.40-1.1%₹1,924.60₹1,940.40₹1,863.502,871,410
₹1,926.90-42.10-2.1%₹1,975.00₹1,981.00₹1,915.601,538,262
₹1,969.000.000.0%₹1,969.00₹1,969.00₹1,969.000
₹1,969.00+24.00+1.2%₹1,943.00₹1,981.80₹1,918.102,277,375
₹1,945.00+8.00+0.4%₹1,932.60₹1,950.50₹1,920.901,067,622
₹1,937.00-9.90-0.5%₹1,946.90₹1,955.00₹1,917.901,822,218
₹1,946.90+106.90+5.8%₹1,870.80₹1,952.00₹1,862.702,115,447
₹1,840.000.000.0%₹1,840.00₹1,840.00₹1,840.000
₹1,840.00-28.50-1.5%₹1,855.00₹1,871.80₹1,835.201,075,943
₹1,868.50+4.50+0.2%₹1,864.90₹1,876.60₹1,852.601,506,361
₹1,864.00+2.40+0.1%₹1,853.20₹1,864.40₹1,811.702,265,630
₹1,861.60-53.40-2.8%₹1,888.90₹1,895.00₹1,837.403,530,385
₹1,915.00-23.50-1.2%₹1,945.00₹1,949.00₹1,847.8030,995,343
₹1,938.50+9.10+0.5%₹1,929.70₹1,938.50₹1,910.102,231,476
₹1,929.40+42.40+2.2%₹1,891.30₹1,930.00₹1,878.404,249,869
₹1,887.00+20.80+1.1%₹1,871.10₹1,898.30₹1,857.403,334,188
₹1,866.20+65.20+3.6%₹1,808.00₹1,869.40₹1,796.503,550,945
₹1,801.00-1.00-0.1%₹1,800.00₹1,810.80₹1,790.002,894,242
₹1,802.00-23.00-1.3%₹1,825.00₹1,836.40₹1,790.301,401,995
₹1,825.00+23.20+1.3%₹1,819.00₹1,832.00₹1,813.801,315,065

Splits

1 split · NSE:LAURUSLABS · every price before a split is adjusted for it

DayRatioWhat
5-for-1Split
Ticker
NSE:LAURUSLABS
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NSE
Currency
INR

What changed lately

Latest news

All Laurus Labs Ltd. news

Laurus Labs Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
4 in the last 12 months · 40 in all · newest Oct 29, 2026 · oldest 2020
Calls
2 calls with a replay · 2 with a transcript · latest Oct 29, 2026
Decks
43 decks · latest Oct 29, 2026

Where Laurus Labs Ltd. is listed

ListingExchangeCountryCurrency
NSE:LAURUSLABS · Home listing · This pageNSEIndiaINR
BSE:LAURUSLABSBSEIndiaINR

Valuation

P/E 92.5× against a median of 39.5×: the highest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
₹1.27T INR
P/E
92.5×
EV/sales
16.2×
EV/EBITDA
53.2×
Price/book
20.5×
Gross margin
48.0%
Operating margin
24.1%
Net margin
17.1%
Debt to equity
0.4×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Laurus Labs Ltd. · NSE:LAURUSLABSUS$13.38BUS$13.66B92.5×16.2×53.2×20.5×17.1%0.4×n/a
Yunnan Baiyao Group Co. Ltd. Class A · SZSE:000538US$15.07BUS$13.10B19.4×2.0×n/a2.5×12.2%0.0×n/a
Jazz Pharmaceuticals plc · NASDAQ:JAZZUS$14.95BUS$18.48B72.6×3.9×n/a3.6×4.4%1.3×0.64
Ipsen SA · EURONEXT:IPNUS$14.62BUS$13.51B30.0×3.4×11.2×2.8×12.1%0.2×n/a
Zydus Lifesciences Limited · NSE:ZYDUSLIFEUS$12.92BUS$13.86B28.6×4.2×17.9×4.3×13.8%0.5×n/a
Elanco Animal Health Incorporated · NYSE:ELANUS$12.87BUS$15.85Bn/a3.1×13.1×1.9×−2.9%0.5×1.20
Dr. Reddy's Laboratories Ltd. · NSE:DRREDDYUS$12.50BUS$12.45B41.4×3.5×22.6×3.0×8.5%0.2×n/a
Cipla Ltd · NSE:CIPLAUS$12.34BUS$11.26B39.5×3.7×21.6×3.2×10.4%0.0×n/a
Mankind Pharma Ltd. · NSE:MANKINDUS$11.88BUS$12.18B49.1×7.3×27.7×6.3×14.6%0.3×n/a
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A · SSE:600436US$11.62BUS$11.29B58.9×9.5×n/a5.5×16.7%0.0×n/a
Aurobindo Pharma Ltd · NSE:AUROPHARMAUS$11.17BUS$11.02B25.9×2.8×13.4×2.6×10.8%0.2×n/a
Median of the othersUS$12.68BUS$12.78B39.5×3.6×17.9×3.1×11.5%0.2×0.92

Forecasts

Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
2156.29 INR · Analysts' mean
EPS, year to Mar 2027
30.05 · 13 analysts
Revenue, year to Mar 2027
86.49B · 15 analysts

Team and board

Officers

OfficerRole
Satyanarayana ChavaExecutive Director and Chief Executive Officer
Ch. Sita RamaiahExecutive Vice President - Finance
V. V. Ravi KumarExecutive Director and Chief Financial Officer
Srinivasa Rao SPresident - Manufacturing and Operations
Suresh PodaPresident - Advanced biologics
Thomas VersoskyPresident - FDF, North America
V Uma Maheswer RaoPresident - Chemical R&D
Arnaud MartinEVP & Head Business Development - CDMO
Ch. Venkata Ramana RaoExecutive Vice President - Intellectual Property Management
Jyothi Basu AbbineniExecutive Vice President - Chemical R&D
Martyn Oliver James PeckExecutive Vice President - Business Development
Narasimha Rao ChavaExecutive Vice President - Human Resources
Narasimha Rao DVLExecutive Vice President - Synthesis
Rajaram IyerExecutive Vice President - Portfolio Management
S. Srinivas RaoExecutive Vice President - Manufacturing
Sumeet SobtiSenior Vice President - Supply Chain Management
C. V. Lakshmana RaoExecutive Director – Quality
Krishna Chaitanya ChavaExecutive Director - CDMO Small Molecules
Soumya ChavaExecutive Director - Affordable Medicines

Board

DirectorRole
Ravindranath KancherlaNon-Executive Independent Director and Chairman of the Board
Aruna BhingeNon-Executive Independent Director
C. V. Lakshmana RaoExecutive Director – Quality
Karnam SekarNon-Executive Independent Director
Krishna Chaitanya ChavaExecutive Director - CDMO Small Molecules
Ramesh SubrahmanianNon-Executive Independent Director
Satyanarayana ChavaExecutive Director and Chief Executive Officer
Sekar KarnamNon-Executive Independent Director
Shekhar C. MandeNon-Executive Independent Director
Soumya ChavaExecutive Director - Affordable Medicines
Sutapa BanerjeeNon-Executive Independent Director
V. V. Ravi KumarExecutive Director and Chief Financial Officer

Events

Next results
Jan 22, 2027 (expected)

Calls

CallWhenStatus
Laurus Labs (NSE:LAURUSLABS) Q2 2027 Earnings CallThu, Oct 29, 2026 · 11:33 AM ETReplay
Laurus Labs (NSE:LAURUSLABS) Q1 2027 Earnings CallFri, Jul 24, 2026 · 1:32 PM ETReplay

Results days

QuarterResultsShare move
Q2 2027Oct 29, 2026 · Before open+2.9%
Q1 2027Jul 24, 2026 · Before open+2.1%
Q4 2026Apr 30, 2026 · Before open−0.5%
Q3 2026Jan 23, 2026 · Before open+1.1%
Q2 2026Oct 23, 2025 · Before open+1.1%
Q1 2026Jul 25, 2025 · Before open+0.1%
Q4 2025Apr 24, 2025 · Before open−0.8%
Q3 2025Jan 24, 2025 · Before open+3.0%
Q2 2025Oct 24, 2024 · Before open−0.5%
Q1 2025Jul 25, 2024 · Before open−0.2%
All 20 quarters
QuarterResultsShare move
Q4 2024Apr 25, 2024 · Before open−2.0%
Q3 2024Jan 24, 2024 · Before open+0.5%
Q2 2024Oct 20, 2023 · Before open+1.1%
Q1 2024Jul 27, 2023 · Before open+0.8%
Q4 2023Apr 27, 2023 · Before open−2.6%
Q3 2023Jan 30, 2023 · Before open−0.0%
Q2 2023Oct 21, 2022 · Before open−7.6%
Q1 2023Jul 27, 2022 · Before open+6.1%
Q4 2022Apr 28, 2022 · Before open−1.3%
Q3 2022Jan 27, 2022 · Before open−2.2%

Open Events

Decks

DeckKindSlidesDate
Q2 FY2027 Earnings PresentationEarnings26 slidesOct 29, 2026
Investor Presentation (September 2026)Investor deck22 slidesSep 18, 2026
Q1 FY2027 Earnings PresentationEarnings21 slidesJul 24, 2026
FY2026 Earnings PresentationEarnings30 slidesApr 30, 2026
Q3 FY2026 Earnings PresentationEarnings26 slidesJan 23, 2026
Q2 FY2026 Earnings PresentationEarnings28 slidesOct 23, 2025
Investor Presentation (September 2025)Investor deck24 slidesSep 12, 2025
Q1 FY2026 Earnings PresentationEarnings24 slidesJul 25, 2025
FY2025 Earnings PresentationEarnings36 slidesApr 24, 2025
Q3 FY2025 Earnings PresentationEarnings31 slidesJan 24, 2025
All 43 decks
DeckKindSlidesDate
Q2 FY2025 Earnings PresentationEarnings33 slidesOct 24, 2024
Q1 FY2025 Earnings PresentationEarnings31 slidesJul 25, 2024
FY2024 Earnings PresentationEarnings42 slidesApr 25, 2024
Q3 FY2024 Earnings PresentationEarnings32 slidesJan 24, 2024
Investor Presentation (November 2023)Investor deck32 slidesNov 24, 2023
Q2 FY2024 Earnings PresentationEarnings32 slidesOct 20, 2023
Q1 FY2024 Earnings PresentationEarnings28 slidesJul 27, 2023
FY2023 Earnings PresentationEarnings41 slidesApr 27, 2023
Q3 FY2023 Earnings PresentationEarnings31 slidesJan 30, 2023
Q2 FY2023 Earnings PresentationEarnings31 slidesOct 21, 2022
Q1 FY2023 Earnings PresentationEarnings27 slidesJul 27, 2022
Q4 FY2022 Earnings PresentationEarnings38 slidesApr 28, 2022
Q3 FY2022 Earnings PresentationEarnings36 slidesJan 27, 2022
Q2 FY2022 Earnings PresentationEarnings35 slidesOct 28, 2021
Q1 FY2022 Earnings PresentationEarnings32 slidesJul 29, 2021
Q4 FY21 Earnings PresentationEarnings25 slidesApr 29, 2021
Q3 FY21 Earnings PresentationEarnings24 slidesJan 28, 2021
Merger or Acquisition (November 2020)Merger or acquisition16 slidesNov 25, 2020
Q2 FY21 Earnings PresentationEarnings23 slidesOct 29, 2020
Q1 FY2021 Earnings PresentationEarnings25 slidesJul 30, 2020
Q4 FY20 Earnings PresentationEarnings33 slidesApr 30, 2020
Q3 FY20 Earnings PresentationEarnings30 slidesFeb 4, 2020
Q2 FY20 Earnings PresentationEarnings30 slidesOct 31, 2019
Q1 FY20 Earnings PresentationEarnings29 slidesAug 2, 2019
Q4 FY2019 Earnings PresentationEarnings27 slidesMay 2, 2019
Q3 FY2019 Earnings PresentationEarnings24 slidesJan 31, 2019
Q2 FY19 Earnings PresentationEarnings27 slidesNov 1, 2018
Q1 FY2019 Earnings PresentationEarnings22 slidesAug 3, 2018
Q4 FY18 Earnings PresentationEarnings25 slidesMay 10, 2018
Q3 & 9M FY18 Earnings PresentationEarnings23 slidesJan 29, 2018
H1 FY2018 Earnings PresentationEarnings24 slidesNov 9, 2017
Q4 FY2017 Earnings PresentationEarnings27 slidesMay 18, 2017
Q3 FY2017 Earnings PresentationEarnings26 slidesFeb 9, 2017

Open Decks

Financials

Annual, in INR

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue68.1B55.5B50.4B60.4B49.4B48.1B28.3B22.9B20.6B19.0B
Cost of revenue40.7B25.9B25.4B28.6B22.5B22.0B14.5B12.6B10.8B10.1B
Gross profit27.4B29.7B25.0B31.8B26.9B26.1B13.9B10.3B9.72B8.91B
Research and development276.6M553.0M437.6M255.9M294.7M172.9M151.8M131.5M134.5M119.2M
Selling, general and administrative2.43B7.23B6.42B5.83B5.04B4.36B3.49B2.98B2.65B2.30B
Operating income13.0B21.7B18.0B25.6B21.5B21.6B10.2B7.11B7.02B6.56B
Depreciation and amortization4.80B4.30B3.85B3.24B2.51B2.05B1.87B1.64B1.25B1.06B
EBITDA17.8B26.0B21.9B28.8B24.0B23.6B12.0B8.75B8.28B7.62B
Interest expense1.71B2.13B1.80B1.43B919.6M663.8M786.0M766.6M729.3M969.9M
Income before tax11.8B4.88B2.30B11.1B10.8B13.0B2.94B1.20B2.37B2.34B
Income tax2.92B1.30B681.5M3.12B2.51B3.17B383.4M259.9M698.1M438.6M
Net income8.89B3.58B1.61B7.90B8.28B9.84B2.55B937.6M1.68B1.90B
Earnings per share, basic16.456.642.9714.6415.3518.284.791.763.154.18

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents1.14B995.4M1.39B456.7M753.5M484.6M16.9M29.7M30.0M24.2M
Short-term investments443.9M24.2M27.9M5.90M390.7M880.0K270.0K-668.3M-651.2M
Receivables21.6B20.4B17.0B16.3B13.9B13.6B8.52B7.42B6.02B6.02B
Inventory23.4B19.4B18.5B16.8B17.6B15.8B9.05B6.82B5.85B5.09B
Current assets48.3B43.3B38.3B34.6B33.4B30.7B18.1B14.6B12.5B11.4B
Property, plant and equipment43.2B40.5B37.0B32.1B22.8B17.7B17.2B16.3B13.6B
Goodwill2.46B2.46B2.46B2.46B2.46B2.46B97.4M97.4M97.4M97.4M
Total assets105.1B93.4B83.9B76.6B69.7B57.5B37.5B33.3B30.2B26.5B
Accounts payable12.5B9.58B10.5B7.11B8.76B11.8B6.16B4.88B3.12B2.63B
Current liabilities36.4B35.4B31.1B24.3B26.8B24.6B16.9B14.2B13.1B11.3B
Long-term debt6.11B6.46B7.98B7.61B5.96B4.29B1.64B2.57B1.38B1.19B
Total debt25.2B27.6B25.8B20.2B17.8B14.8B10.8B10.4B9.80B8.42B
Total liabilities50.8B47.3B42.7B36.1B36.1B31.5B19.8B17.7B15.3B13.2B
Shareholders' equity53.0B44.7B41.1B40.4B33.5B26.0B17.7B15.6B14.8B13.3B
Shares outstanding540.3M539.6M539.7M539.6M539.2M538.1M533.5M532.6M531.7M455.2M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations14.6B6.02B6.66B9.94B9.11B7.33B3.47B2.98B3.42B3.32B
Capital spending-10.7B-6.41B-6.78B-9.90B-8.77B-6.89B-2.22B-2.54B-3.91B-2.77B
Free cash flow3.89B-393.5M-126.2M37.4M342.6M442.3M1.25B434.0M-486.2M544.9M
Cash from investing-11.0B-6.82B-8.22B-9.96B-9.14B-9.41B-2.21B-2.53B-3.84B-2.89B
Cash from financing-3.54B392.8M2.50B-266.4M302.6M2.55B-1.28B-447.7M422.4M-536.1M
Dividends paid-863.3M-431.3M-861.8M-1.07B-858.6M-750.4M-320.0M-159.0M-158.6M-49.3M
Share buybacks101.7M25.6M2.39B1.63B883.5M73.7M538.3M1.68B1.05B
Change in cash138.8M-394.0M932.7M-296.8M268.9M467.7M-12.8M-360.0K5.81M-103.8M

Open Financials

Filings

FilingDateTypeFiled with
Laurus Labs Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.".Oct 29, 2026ResultsNSE India
Laurus Labs Ltd. Press Release Jul 24 2026Jul 24, 2026ResultsNSE India
Press Release Apr 30 2026Apr 30, 2026ResultsNSE India
Press Release Jan 23 2026Jan 23, 2026ResultsNSE India
Press Release Oct 23 2025Oct 23, 2025ResultsNSE India
Press Release Jul 25 2025Jul 25, 2025ResultsNSE India
Press Release Apr 24 2025Apr 24, 2025ResultsNSE India
Press Release Jan 24 2025Jan 24, 2025Other filingsNSE India
Press Release Dec 06 2024Dec 6, 2024Other filingsNSE India
Press Release Oct 24 2024Oct 24, 2024ResultsNSE India
All 39 filings
FilingDateTypeFiled with
Press Release Sep 16 2024Sep 16, 2024Operations updateNSE India
Press Release Sep 13 2024Sep 13, 2024Operations updateNSE India
Press Release Jul 25 2024Jul 25, 2024Other filingsNSE India
Press Release Apr 25 2024Apr 25, 2024Other filingsNSE India
Press Release Jan 25 2024Jan 25, 2024Other filingsNSE India
Press Release Jan 24 2024Jan 24, 2024ResultsNSE India
Press Release Oct 20 2023Oct 20, 2023Other filingsNSE India
Press Release Jul 27 2023Jul 27, 2023ResultsNSE India
Press Release Jun 19 2023Jun 19, 2023Operations updateNSE India
Press Release May 31 2023May 31, 2023Other filingsNSE India
Press Release May 02 2023May 2, 2023Operations updateNSE India
Press Release Apr 27 2023Apr 27, 2023ResultsNSE India
Press Release Jan 30 2023Jan 30, 2023ResultsNSE India
Press Release Oct 21 2022Oct 21, 2022ResultsNSE India
Press Release Jul 27 2022Jul 27, 2022ResultsNSE India
Press Release Apr 28 2022Apr 28, 2022ResultsNSE India
Press Release Jan 27 2022Jan 27, 2022Other filingsNSE India
Press Release Jan 21 2022Jan 21, 2022Other filingsNSE India
Press Release Nov 19 2021Nov 19, 2021Acquisition or disposalNSE India
Press Release Oct 28 2021Oct 28, 2021Other filingsNSE India
Press Release Sep 14 2021Sep 14, 2021Operations updateNSE India
Press Release Jul 29 2021Jul 29, 2021ResultsNSE India
Press Release Jul 02 2021Jul 2, 2021Other filingsNSE India
Press Release Apr 29 2021Apr 29, 2021ResultsNSE India
Press Release Mar 04 2021Mar 4, 2021Ownership change noticeNSE India
Press Release Feb 10 2021Feb 10, 2021Other filingsNSE India
Press Release Jan 28 2021Jan 28, 2021ResultsNSE India
Press Release Nov 25 2020Nov 25, 2020Acquisition or disposalNSE India
Press Release Oct 29 2020Oct 29, 2020ResultsNSE India

Open Filings

Cap table

Built by 6ix from Laurus Labs Ltd.’s releases

Common shares
540,312,218
Fully diluted
540,312,218

Fully diluted

LineShares
Common shares540,312,218

Share count over time

CountShares
Nov 22, 2026540,312,218

Open Cap table

Shareholders

HolderSharesValueAs of
New World Fund Inc20.4MUS$387MJul 31, 2026
SMALLCAP World Fund Inc14.9MUS$241MJun 30, 2026
Vanguard Total International Stock Index Fund5.4MUS$103MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund5.15MUS$98MJul 31, 2026
iShares Core MSCI Emerging Markets ETF4.1MUS$58.8MMay 31, 2026
Emerging Markets Core Equity 2 Portfolio2.15MUS$40.8MJul 31, 2026
Goldman Sachs Emerging Markets Equity Insights Fund1.49MUS$28.4MJul 31, 2026
New World Fund1.15MUS$18.6MJun 30, 2026
Capital Group New Geography Equity ETF863KUS$12.4MMay 31, 2026
Vanguard Ftse All-World Ex-Us Index Fund862KUS$16.4MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
iShares MSCI India Small-Cap ETF624KUS$8.94MMay 31, 2026
Franklin FTSE India ETF602KUS$9.65MJun 30, 2026
iShares Core MSCI Total International Stock ETF551KUS$10.5MJul 31, 2026
WisdomTree India Earnings Fund524KUS$8.39MJun 30, 2026
Dimensional Emerging Markets Core Equity 2 ETF505KUS$9.62MJul 31, 2026
The Emerging Markets Small Cap Series469KUS$8.91MJul 31, 2026
SMALLCAP World Fund444KUS$7.16MJun 30, 2026
Emerging Markets Portfolio432KUS$6.94MJun 30, 2026
Schwab Emerging Markets Equity ETF429KUS$6.15MMay 31, 2026
Avantis Emerging Markets Equity ETF422KUS$6.04MMay 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF378KUS$6.07MJun 30, 2026
The Emerging Markets Series299KUS$5.7MJul 31, 2026
Vanguard Total World Stock Index Fund295KUS$5.61MJul 31, 2026
Dimensional Emerging Core Equity Market ETF281KUS$5.36MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account255KUS$4.1MJun 30, 2026
Fidelity Total International Index Fund207KUS$3.93MJul 31, 2026
Columbia EM Core ex-China ETF187KUS$2.99MJun 30, 2026
Dimensional World ex. U.S. Core Equity 2 ETF162KUS$3.09MJul 31, 2026
William Blair Emerging Markets Small Cap Growth Fund162KUS$2.6MJun 30, 2026
NVIT GS Emerging Markets Equity Insights Fund135KUS$2.18MJun 30, 2026
American Beacon IMC International Small Cap Fund118KUS$2.24MJul 31, 2026
WisdomTree Emerging Markets ex-State-Owned Enterprises Fund117KUS$1.87MJun 30, 2026
VictoryShares Emerging Markets Value Momentum ETF116KUS$1.87MJun 30, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio116KUS$1.86MJun 30, 2026
iShares MSCI Emerging Markets Small-Cap ETF89,900US$1.29MMay 31, 2026
Fidelity SAI Emerging Markets Momentum Index Fund87,975US$1.68MJul 31, 2026
Thrivent Core Emerging Markets Equity Fund78,196US$1.49MJul 31, 2026
Hartford Emerging Markets Equity Fund77,900US$1.48MJul 31, 2026
American Beacon Ninety One Emerging Markets Equity Fund72,942US$1.05MMay 31, 2026
Vanguard ESG International Stock ETF70,787US$1.01MMay 31, 2026
World ex U.S. Core Equity Portfolio57,587US$1.1MJul 31, 2026
Goldman Sachs India Equity ETF54,865US$787KMay 31, 2026
Thrivent International Equity Portfolio52,650US$845KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Emerging Asia Pacific ETF50,039US$802KJun 30, 2026
Emerging Markets Social Core Equity Portfolio44,226US$841KJul 31, 2026
Emerging Markets ex China Core Equity Portfolio38,904US$740KJul 31, 2026
John Hancock Multifactor Emerging Markets ETF36,010US$577KJun 30, 2026
Thrivent International Equity Fund30,671US$584KJul 31, 2026
State Street(R) SPDR(R) Portfolio MSCI Global Stock Market ETF30,549US$490KJun 30, 2026
Avantis Emerging Markets Value ETF29,514US$423KMay 31, 2026

This page holds 50 of 79 holders. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Arnaud MartinEVP & Head Business Development - CDMO · Since at least Nov 4, 2026
Aruna BhingeNon-Executive Independent Director · Since at least Nov 6, 2026
Ch. Sita RamaiahExecutive Vice President - Finance · Since at least Nov 4, 2026
Ch. Venkata Ramana RaoExecutive Vice President - Intellectual Property Management · Since at least Nov 4, 2026
Jyothi Basu AbbineniExecutive Vice President - Chemical R&D · Since at least Nov 4, 2026
Karnam SekarNon-Executive Independent Director · Since at least Nov 4, 2026
Krishna Chaitanya ChavaExecutive Director - CDMO Small Molecules · Since at least Nov 6, 2026
Lakshmana Rao C VExecutive Director – Quality · Since at least Nov 6, 2026
Martyn Oliver James PeckExecutive Vice President - Business Development · Since at least Nov 4, 2026
Narasimha Rao ChavaExecutive Vice President - Human Resources · Since at least Nov 4, 2026
All 26 people
PersonSeat
Narasimha Rao DVLExecutive Vice President - Synthesis · Since at least Nov 4, 2026
Rajaram IyerExecutive Vice President - Portfolio Management · Since at least Nov 4, 2026
Ramesh SubrahmanianNon-Executive Independent Director · Since at least Nov 6, 2026
Ravindranath KancherlaNon-Executive Independent Director and Chairman of the Board · Since at least Nov 6, 2026
Satyanarayana ChavaExecutive Director and Chief Executive Officer · Since at least Oct 8, 2025
Sekar KarnamNon-Executive Independent Director · Since at least Nov 6, 2026
Shekhar C. MandeNon-Executive Independent Director · Since at least Nov 6, 2026
Soumya ChavaExecutive Director - Affordable Medicines · Since at least Nov 6, 2026
Srinivasa Rao SPresident - Manufacturing and Operations · Since at least Nov 4, 2026
S. Srinivas RaoExecutive Vice President - Manufacturing · Since at least Nov 4, 2026
Sumeet SobtiSenior Vice President - Supply Chain Management · Since at least Nov 4, 2026
Suresh PodaPresident - Advanced biologics · Since at least Nov 4, 2026
Sutapa BanerjeeNon-Executive Independent Director · Since at least Nov 6, 2026
Thomas VersoskyPresident - FDF, North America · Since at least Nov 4, 2026
V Uma Maheswer RaoPresident - Chemical R&D · Since at least Nov 4, 2026
V. V. Ravi KumarExecutive Director and Chief Financial Officer · Since at least Nov 6, 2026

Open People

Log in to ask 6ix AI your own questions about Laurus Labs Ltd.